TITLE

Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents

AUTHOR(S)
Alexakis C; Caruelle J P; Sezeur A; Cosnes J; Gendre J P; Mosnier H; Beaugerie L; Gallot D; Malafosse M; Barritault D; Kern P
PUB. DATE
January 2004
SOURCE
Gut;Jan2004, Vol. 53 Issue 1, p85
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Crohn's disease (CD) is characterised by inflammation, muscle layer overgrowth, and collagenous fibrosis of the intestinal tract, with no effective therapy against collagen accumulation. AIMS: We quantified production of collagen in resection specimens from normal and CD patients and investigated the effect of regenerating agents (RGTAs) on collagen production. RGTAs are chemically substituted dextrans engineered to mimic the growth factor protecting effects of heparan sulphates. RGTAs have been shown to enhance tissue repair in various in vivo models and to modulate in vitro collagen phenotype differentially according to their structure. PATIENTS: We studied intestinal biopsies from two groups of CD patients: treated with glucocorticoids (CD-GC group: 10 patients) or not treated (CD group: seven patients), and from seven control patients. METHODS: After 24 hours of ex vivo incubation with (3H) proline, collagen I, III, and V were extracted by pepsin and quantitatively separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Biosynthesis of each collagen type was quantified on radiolabelled isolated collagen. RESULTS: Total intestinal collagen production in CD patients compared with controls was increased up to 3.5-fold overall (p<0.001). In particular, collagen III biosynthesis was enhanced by 6.2-fold (p<0.001) in CD patients. In the CD-GC group, collagen production abnormalities were less marked. RGTAs added to the incubation medium in the CD group decreased total collagen production by 50% and decreased collagen III synthesis by 76%. CONCLUSION: This finding offers a rationale for using RGTAs in the treatment of intestinal fibrosis in CD, thus opening up a potential new therapeutic field for this family of drugs.
ACCESSION #
12136745

 

Related Articles

  • Can an Immunohistochemistry Method Differentiate Intestinal Tuberculosis from Crohn's Disease in Biopsy Specimens? İnce, Ali; Güneş, Pembegül; Şenateş, Ebubekir; Sezikli, Mesut; Tiftikçi, Arzu; Övünç, Oya // Digestive Diseases & Sciences;Apr2011, Vol. 56 Issue 4, p1165 

    Background: It is sometimes difficult to diagnose whether a patient has intestinal tuberculosis or Crohn's disease because both have similar clinical, pathologic, and endoscopic features. However, their therapies are completely different and a mistake in diagnosis can result with deterioration....

  • Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy therapy. Leal, Raquel Franco; Planell, Nuria; Kajekar, Radhika; Lozano, Juan J.; Ordás, Ingrid; Dotti, Isabella; Esteller, Miriam; Masamunt, M. Carme; Parmar, Harsukh; Ricart, Elena; Panés, Julián; Salas, Azucena // Gut;Feb2015, Vol. 64 Issue 2, p233 

    Background Anti-tumour necrosis factor a (TNFα) therapy effectively induces and maintains remission in Crohn's disease (CD). Up to 40% of patients, however, fail to respond to anti-TNFα. Objective To identify the mechanisms underlying the persistence of mucosal lesions in patients who fail...

  • Isolation of Mycobacterium avium Subspecies paratuberculosis Reactive CD4 T Cells from Intestinal Biopsies of Crohn's Disease Patients. Olsen, Ingrid; Tollefsen, Stig; Aagaard, Claus; Reitan, Liv J.; Bannantine, John P.; Andersen, Peter; Sollid, Ludvig M.; Lundin, Knut E. A. // PLoS ONE;2009, Vol. 4 Issue 5, p1 

    Background: Crohn's disease (CD) is a chronic granulomatous inflammation of the intestine. The etiology is unknown, but an excessive immune response to bacteria in genetically susceptible individuals is probably involved. The response is characterized by a strong Th1/Th17 response, but the...

  • Variable impact of CD39 in experimental murine colitis. Künzli, Beat; Berberat, Pascal; Dwyer, Karen; Deaglio, Silvia; Csizmadia, Eva; Cowan, Peter; d'Apice, Anthony; Moore, Gregory; Enjyoji, Keiichi; Friess, Helmut; Robson, Simon; Künzli, Beat M; Berberat, Pascal O; Robson, Simon C // Digestive Diseases & Sciences;May2011, Vol. 56 Issue 5, p1393 

    Background: Dysregulation of immune responses in inflammatory bowel diseases (IBD) results in intestinal inflammation and vascular injury while exacerbating systemic disease. CD39 is an ectonucleotidase, expressed by T regulatory cells and dendritic cells, that hydrolyzes...

  • The Fynbos and Succulent Karoo Biomes Do Not Have Exceptional Local Ant Richness. Braschler, Brigitte; Chown, Steven L.; Gaston, Kevin J. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Background: The Fynbos (FB) and Succulent Karoo biomes (SKB) have high regional plant diversity despite relatively low productivity. Local diversity in the region varies but is moderate. For insects, previous work suggests that strict phytophages, but not other taxa, may have high regional...

  • L-arginine Supplementation Improves Responses to Injury and Inflammation in Dextran Sulfate Sodium Colitis. Coburn, Lori A.; Xue Gong; Singh, Kshipra; Asim, Mohammad; Scull, Brooks P.; Allaman, Margaret M.; Williams, Christopher S.; Rosen, Michael J.; Washington, M. Kay; Barry, Daniel P.; Piazuelo, M. Blanca; Casero, Jr., Robert A.; Chaturvedi, Rupesh; Zhongming Zhao; Wilson, Keith T. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Inflammatory bowel disease (IBD), consisting of Crohn's disease and ulcerative colitis (UC), results in substantial morbidity and is difficult to treat. New strategies for adjunct therapies are needed. One candidate is the semi-essential amino acid, Larginine (L-Arg), a complementary medicine...

  • Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Schmidt, Nicole; Gonzalez, Erik; Visekruna, Alexander; Kñ/4hl, Anja A.; Loddenkemper, Christoph; Mollenkopf, Hans; Kaufmann, Stefan H. E.; Steinhoff, Ulrich; Joeris, Thorsten // Gut;Jul2010, Vol. 59 Issue 7, p896 

    Background and aims Inflammatory bowel disease (IBD), comprising Crohn's disease and ulcerative colitis, is characterised by chronic relapsing inflammation of the gut. Increased proteasome activity, associated with the expression of immunoproteasomes, was found to enhance proinflammatory...

  • Immunoregulatory function of PIR-A/B DCs in the inflammatory responses of dextran sodium sulfate-induced colitis. Kurishima, Akiko; Inaba, Muneo; Sakaguchi, Yutaku; Fukui, Toshiro; Uchida, Kazushige; Nishio, Akiyoshi; Nomura, Shosaku; Okazaki, Kazuichi // Journal of Gastroenterology;Oct2014, Vol. 49 Issue 10, p1367 

    Background: Dendritic cells (DCs) may play an important role in forms of inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis. DCs are generally recognized as initiators of acquired immunity and also serve as regulators of both innate and acquired immunity. We used...

  • Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Demon, D; Kuchmiy, A; Fossoul, A; Zhu, Q; Kanneganti, T-D; Lamkanfi, M // Mucosal Immunology (1933-0219);Nov2014, Vol. 7 Issue 6, p1480 

    Ulcerative colitis and Crohn's disease are major inflammatory syndromes that affect millions of patients. Caspase-11 confers protection against Gram-negative enteropathogens, but its role during colitis is unknown. Here, we show that caspase-11 was constitutively expressed in the colon, and that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics